Recently, the 22nd “Shenzhen Enterprise Innovation Record” was officially announced. The “Key Technology Innovation and Clinical Application Research of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus Erythematosus” project submitted by Shenzhen Beike Biotechnology Co., Ltd. was successfully shortlisted for the “Shenzhen Enterprise Innovation Record” and won the “Innovation Project Award for Product Research and Development”.
“Research on Key Technology Innovation and Clinical Application of Allogeneic Mesenchymal Stem Cells in the Treatment of Refractory Lupus Erythematosus” project is an outstanding achievement of Beike Biotech in the field of clinical transformation of biotherapy technology. For the first time, the project team applied allogeneic mesenchymal stem cells to treat refractory systemic lupus erythematosus. The efficacy was remarkable, with an effective rate of 60%, no serious adverse reactions, and the 5-year mortality rate was reduced from 45% to 16%. The research results not only enrich the basic theory of the pathogenesis of autoimmune diseases, but also open up new ways for the treatment of refractory autoimmune diseases and solve the problem of ineffective conventional treatments for some refractory patients. They have important scientific value and potential clinical application prospects. !important;”> has attracted great attention from domestic and foreign peers, and won the second prize of the National Technology Invention Award in 2019.
Technology empowers development, and innovation leads the future. Beike Biotech has always insisted on promoting the transformation of innovative scientific and technological achievements as an important driving force for corporate development. It has established multiple innovative R&D platforms, solved many technical problems in the industry, and introduced cutting-edge technologies and achievements in the field of translational biotherapy. In recent years, with its core technological advantages in the cell field and its keen control of cutting-edge medical changes, Beike Biotech has frequently launched attacks in the fields of basic cell research, cell storage, metabolomics, new drug research and development, AI intelligence, big data and other fields, and the company’s various businesses have developed rapidly. In the future, Beike Biotech will continue to strive for technological innovation in the fields of clinical transformation of biotherapeutic technologies, accelerate the transformation and clinical application of related technology products, create more innovative products and solutions with independent intellectual property rights, and make greater contributions to the high-quality development of China’s biotechnology industry.